Skip to main content
SpringerLink
Log in

Serum Interleukin-2 and Soluble Interleukin-2 Receptor in Gestational Trophoblastic Diseases

  • Original Article
  • Published:
The Journal of the Society for Gynecologic Investigation: JSGI Aims and scope Submit manuscript

Abstract

Objective

To investigate serum interleukin-2 (IL-2) and soluble interleukin-2 receptor (SIL-2) levels in gestational trophoblastic diseases (GTD).

Methods

Sixty-six patients with GTDs and 23 first-trimester healthy pregnant women (controls) participated in this study. According to the World Health Organization scoring system, GTDs were subgrouped into the following groups: 30 hydatidiform mole spontaneous regression (HMSR), 12 postmolar gestational trophoblastic tumors of high risk (PMHR), 14 low-risk choriocarcinomas, and ten high-risk choriocarcinomas. Before treatment, a blood sample from each case was assayed for β-hCG by radioimmunoassay, IL-2 by IRMA, and SIL-2R by enzyme-linked immunosorbent assay. Follow-up β-hCG assays were carried out at weekly intervals after treatment for 3 months, then monthly for 1 year.

Results

Serum IL-2 levels in all subgroups of GTD were significantly lower than that of controls. Meanwhile, there were concomitant significant elevations of serum SIL-2R, showing mean rises of 3.86-fold, 3.9fold, twofold, and 6.1-fold for cases of HMSR, PMHR, low-risk choriocarcinoma, and high-risk carcinoma, respectively. All cases of high-risk choriocarcinoma revealed abnormally high SIL-2R values. There was a significant positive correlation between serum β-hCG and SIL-2R concentrations.

Conclusion

The possible causes of IL-2 decreases and SIL-2R increases may indicate a defective immune response in GTDs. The high correlation between S1L-2R level and tumor burden suggests the use of serum SIL-2R assay for disease monitoring: SIL-2R is indirect marker of tumor activity, and it is useful in the differential diagnosis of GTD because a normal value of serum SIL-2R excludes high-risk cases of choriocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Goldstein DP, Berkowitz RS. Gestational trophoblastic neoplasms: Clinical principles of diagnosis and management. Philadelphia, WB Saunders 1982:143–75.

    Google Scholar 

  2. Berkowitz RS, Hill JA, Kurtz CB, Anderson DJ. Effects of products of activated leucocytes, lymphokines and monokines on the growth of malignant trophoblastic cells in vitro. Am J Obstet Gynecol, 1988;158:199–206.

    Article  CAS  PubMed  Google Scholar 

  3. Balkrill FR, Burke F. The cytokine network. Immunol Today, 1989;10:299–304.

    Article  Google Scholar 

  4. Ben-Rafael Z, Orieto R. Cytokines involvement in reproduction. Fertil Stenl 1992;58:1093–9.

    Article  CAS  Google Scholar 

  5. Wagnann TG. Maternal T cells promote placental growth and prevent spontaneous abortion. Immunol Lett 1988;17:297–302.

    Article  Google Scholar 

  6. Anderson DJ, Hill JA, Haimovici F, Xu C. Application of new concepts in cell-mediated immunity to the development of effective antifertility vaccines. In: Runnebaum B, Raule T, Kiesel L, eds. Female contraception update and trends. Heidelberg, Germany: Springer-Verlag, 1982;351–5.

    Google Scholar 

  7. Nichols NS, Panayi G. Inhibition of interleukin production by retroplacental sera. Am J Reprod Immunol Microbiol 1985;9:6–11.

    Article  Google Scholar 

  8. Berkowitz RS, Goldstein DP. Diagnosis and management of the primary hydatidiform mole. Obstet Gynecol 1988;15:252–62.

    Google Scholar 

  9. Oppeheim JJ, Ruscetti FW, Faltynek C. Cytokines. In: Stites DP, Terr Al, eds. Basic and clinical immunology. 7th ed. Nor-walk, Connecticut: Appleton & Lange, 1991:78–100.

    Google Scholar 

  10. Mills GB, Hashimoto S, Hurteau JA, et al. Role of growth factors, their receptors, and oncogenes in the diagnosis, prognosis, follow-up and therapy of ovarian cancer. Diagn Oncol 1992;2: 39–54.

    Google Scholar 

  11. Waldmann TA. The interleukin 2 receptor. J Biol Chem 1991; 266:2681–4.

    CAS  PubMed  Google Scholar 

  12. Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135:3172–7.

    CAS  PubMed  Google Scholar 

  13. Rubin LA, Nelson D. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113:619–45.

    Article  CAS  PubMed  Google Scholar 

  14. Dianarello CA, Mier JW. Lymphokines. N Engl J Med 1987; 317:940–45.

    Article  Google Scholar 

  15. Oliver RTD. The clinical potential of interleukin-2. Br J Cancer 1988;58:405–09.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Leo R, Peest R, Hein R, et al. Low-dose subcutaneous interleukin-2 in human multiple myeloma, current results of a phase I/II pilot study. In: Freund M, Link RE, Schmidt E, Welte K, eds. Cytokines in hemopoiesis, oncology and AIDS II. Berlin Heidelberg, Germany: Springer-Verlag, 1992:747–55.

    Chapter  Google Scholar 

  17. Blaise D, Stoppa AM, Olive D, et al. Treatment of relapsed acute leukemias with systemic rIL-2. In: Freund M, Link RE, Schmidt E, Welte K, eds. Cytokines in hemopoiesis, oncology and AIDS II. Berlin Heidelberg, Germany: Springer-Verlag, 1992:763–8.

    Chapter  Google Scholar 

  18. Hall SS. IL-12 holds promise against cancer, glimmer of AIDS hope. Science 1994;263:1684–5.

    Article  Google Scholar 

  19. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985;318:745–7.

    Article  Google Scholar 

  20. Jarousseau AC, Thibault G, Reverdiau P, et al. Adhesion properties of choriocarcinoma cells towards lymphocytes activated or not by interleukin-2. Cell Immunol 1994;157:38–47.

    Article  CAS  PubMed  Google Scholar 

  21. Lindemann A. Brossart P, Hoffken K, et al. Serum cytokine levels in cancer patients treated with different schedules of ultra-low-dose interleukin-2. J Immunother Emphasis Tumor Immunol 1994;15:225–30.

    Article  CAS  PubMed  Google Scholar 

  22. Guillauir T, Sekhavat M, Rubinstein DB, Hamdan O, Leblanc P, Symann ML. Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution. Cancer Res 1994;54:3800–7.

    Google Scholar 

  23. Crispino S, Lissoni P, Ardizzoia A, et al. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients. J Biol Regul Homeost Agents 1993;7:92–4.

    CAS  PubMed  Google Scholar 

  24. Elasser BU, Gallati H, Weber W, Wild ED, Schultd- Monting J, von- Kleist S. Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients. Tumor Biol 1994;15:17–24.

    Article  Google Scholar 

  25. Murakami S, Satomi A, Ishida K, Murai H, Okamura Y. Serum soluble interleukin-2 receptor in colorectal cancer. Acta Oncol 1994;33:19–21.

    Article  CAS  PubMed  Google Scholar 

  26. Lotze MT, Custer MC, Sharrow SO, Rubm LA, Nelson DL, Rosenberg SA. In vivo administration of purified human interleukin-2 to patients with cancer: Development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res 1987;47:2188–95.

    CAS  PubMed  Google Scholar 

  27. Muller C, Knoflach P, Zielinski C. Soluble interleukin-2 receptor in acute and viral hepatitis and chronic liver disease. Hepa-tology 1989;19:928–32.

    Google Scholar 

  28. Kloster BE, John PA, Miller LE, et al. Soluble interleukin-2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol 1987;45:440–6.

    Article  CAS  PubMed  Google Scholar 

  29. Semenzato G, Cipriani A, Trentin I, et al. High serum levels of soluble interleukin-2 receptors in sarcoidosis. Sarcoidosis 1987; 4:25–7.

    CAS  PubMed  Google Scholar 

  30. Nakanishi K, Taniguch Y. Increased levels of soluble interleukin-2 receptors in Graves disease. Proceedings of the 8th International Congress of Endocrinology, Kyoto, Japan, July 17—23, 1988:267.

    Google Scholar 

  31. Colvin KB, Fuller TC, Mackenn I, Kung PC, IP SH, Cosimi AB. Plasma interleukin 2 receptor levels in renal allograft recipient. Clin Immunol Immunopathol 1987;43:273–76.

    Article  CAS  PubMed  Google Scholar 

  32. Stole V, Krause JR. Interleukin-2 receptor levels are increased in blood of heart transplant patients during infections. Diagn Clin Immunol 1987;43:273–8.

    Google Scholar 

  33. Wagner DK, Kiwanuka J, Brenda K, Rubbin LA, Nelson DL, Magrath IT. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: Correlation with survival. J Clin Oncol 1987;5:1262–74.

    Article  CAS  PubMed  Google Scholar 

  34. Chilosi M, Pizzolo G, Semenzato G, Cetto G. Detection of a soluble form of the receptor for interleukin-2 in the serum of patients with hair cell leukemia. IntJ Biol Markers 1986;1:101–4.

    Article  CAS  Google Scholar 

  35. Pizzalo G, Chilosi M, Vinante F, et al. Soluble interleukin-2 receptors in the serum of patients with Hodgkin’s disease. Br J Cancer 1987;55:427–8.

    Article  Google Scholar 

  36. Rovelli F, Lissoni P, Crisino S, et al. Increased levels of soluble interleukin-2 receptor in advanced solid tumors, a preliminary study. Tumon 1988;47:633–7.

    Google Scholar 

  37. Lissoni B, Barini S, Rovelli F, et al. The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer 1990;26:32–6.

    Google Scholar 

  38. Buccheri G, Marino P, Preatom A, Ferrigno D, Moroni GA. An indirect marker of tumor activity. Chest 1991;99:1433–6.

    Article  CAS  PubMed  Google Scholar 

  39. Cetingul N, Yener E, Oztop S, Nisli G. Serum soluble interleu-kin-2 receptors and tumor necrosis factor-alpha in hematological malignancies of childhood. Acta Paediatr 1994;36:49–52.

    Article  CAS  Google Scholar 

  40. Change SC, Hsu YT, Chen YC, Lin CY. Usefulness of soluble interleukin-2 receptors in differentiating tuberculous and carcinomatous pleural effusions. Arch Intern Med 1994; 154:1097–101.

    Article  Google Scholar 

  41. Hurteau JA, Simon HU, Kurman C, Rubin L, Mills GB. Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. Am J Obstet Gynecol 1994;170:918–28.

    Article  CAS  PubMed  Google Scholar 

  42. Ferdeghini M, Gadducci A, Prontera C, et al. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer. Tumor Biol 1993;14:303–9.

    Article  CAS  Google Scholar 

  43. Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, To-monaga M. Significance of soluble mterleukin-2 receptor levels for evaluation of the progression of adult T cell leukemia. Cancer 1994;73:2753–8.

    Article  CAS  PubMed  Google Scholar 

  44. Nicholas NS, Panayi GS, Nouri AME. Human pregnancy serum inhibits interleukin-2 production. Clin Exp Immunol 1984;58: 587–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Lissoni P, Barini S, Rescaldani R, Rovelli F, Tacini G. Serum levels of soluble interleukin-2 receptors and their relation to lymphocyte subpopulations in patients with metastatic solid tumors. Br J Cancer 1989;60:616–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Lissoni P, Barni S, Rovelli S. et al. Correlation of serum interleukin-2 levels, soluble interleukin-2 receptors and T-lymphocyte subsets in cancer patients. Tumori 1990;76:14–7.

    Article  CAS  PubMed  Google Scholar 

  47. Schirrmacher B, Josomovic-Alasevic O, Osawa H, Dianantstem T. Determination of cell-free interleukin-2 receptor level in the serum of normal animals and of animals bearing IL-2 receptor positive tumours with high or low metastatic capacity. Br J Cancer 1987;55:583–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Rubin LA, Jay G, Nelson DL. The released interleukin-2 receptor binds interleukm-2 efficiently. J Immunol 1986;137:3841–4.

    CAS  PubMed  Google Scholar 

  49. Schlaerth JB. Molar pregnancy termination. Clin Obstet Gynecol 1984;27:1–8.

    Article  Google Scholar 

  50. Berkowitz RS, Goldstein DP, Marean NR, Bernstein AM. Oral contraceptives and postmolar trophoblastic disease. Am J Obstet Gynecol 1981;4:474–82.

    Google Scholar 

  51. Quigley MM, Tyrey L, Hamond CB. Utility of assay of alpha subunit of hCG in management of gestational trophoblastic malignancies. Am J Obstet Gynecol 1980;138:545–52.

    Article  CAS  PubMed  Google Scholar 

  52. Lee JM, Salem HT, Al-Aui AT. Circulating concentrations of specific proteins, hCG, SP and PPS in untreated gestational trophoblastic disease. Am J Obstet Gynecol 1991;139:702–14.

    Article  Google Scholar 

  53. Shaarawy M, Nagui A. the diagnostic and prognostic values of serum human chorionic gonadotrophins beta subunits, hPL, (31 pregnancy specific glycoprotein (SP1) and alpha-fetoprotein (AFP) in gestational trophoblastic disease. J Egypt Soc Obstet Gynecol 1983;9:3–12.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, 21 El-Khalifa El-Maamoun Street, Apt. 701, Roxy Building, Heliopolis, Cairo, Egypt

    Mohamed Shaarawy PhD, FRCPath, Nabil A. Darwish MD & Omar Abdel-Aziz MD

Authors
  1. Mohamed Shaarawy PhD, FRCPath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nabil A. Darwish MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Omar Abdel-Aziz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shaarawy, M., Darwish, N.A. & Abdel-Aziz, O. Serum Interleukin-2 and Soluble Interleukin-2 Receptor in Gestational Trophoblastic Diseases. Reprod. Sci. 3, 39–46 (1996). https://doi.org/10.1016/1071-5576(95)00036-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/1071-5576(95)00036-4

Key words

Search

Navigation